Biblio

Export 8 results:
Author Title [ Type(Desc)] Year
Filters: Author is Fox, Nick C  [Clear All Filters]
Journal Article
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
P. S. J. Weston, Paterson, R. W., Dickson, J., Barnes, A., Bomanji, J. B., Kayani, I., Lunn, M. P., Mummery, C. J., Warren, J. D., Rossor, M. N., Fox, N. C., Zetterberg, H., and Schott, J. M., “Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?”, J Alzheimers Dis, vol. 54, no. 4, pp. 1297-1302, 2016.
M. S. Albert, DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., Snyder, P. J., Carrillo, M. C., Thies, B., and Phelps, C. H., “The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.”, Alzheimers Dement, vol. 7, no. 3, pp. 270-9, 2011.
J. Toombs, Foiani, M. S., Paterson, R. W., Heslegrave, A., Wray, S., Schott, J. M., Fox, N. C., Lunn, M. P., Blennow, K., and Zetterberg, H., “Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration.”, J Alzheimers Dis, vol. 56, no. 3, pp. 885-891, 2017.
S. P. Salloway, Sperling, R., Fox, N. C., Sabbagh, M. N., Honig, L. S., Porsteinsson, A. P., Rofael, H., Ketter, N., Wang, D., Liu, E., Carr, S., Black, R. S., and H Brashear, R., “Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.”, J Alzheimers Dis, vol. 64, no. 3, pp. 689-707, 2018.
P. G. Kehoe, Blair, P. S., Howden, B., Thomas, D. L., Malone, I. B., Horwood, J., Clement, C., Selman, L. E., Baber, H., Lane, A., Coulthard, E., Passmore, A. Peter, Fox, N. C., Wilkinson, I. B., and Ben-Shlomo, Y., “The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 803-814, 2018.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.